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Introduction
Myocarditis is simply defined as an inflammatory condition mainly located in the heart muscle, [1] [2] [3] although considerable uncertainties still persist as to its aetiological, pathological and clinical sub-classifications. 4, 5 In addition to the possibility of an aspecific flu-like prodrome, possible presentations include different degrees of heart failure (ranging from cardiogenic shock to subtly progressive chronic heart failure), chest pain, conduction anomalies, brady-and tachyarrhythmias (including sudden cardiac death). The clinical course is also variable, [6] [7] [8] [9] as a spontaneous recovery may occur after the acute phase in up to 50% of patients, while chronic myocarditis and dilated cardiomyopathy sustained by viral persistence and/or autoimmune selfperpetration represent a common evolution of the disease.
Myocarditis may cause arrhythmias both in its acute phase, due to inflammatory infiltration and myocyte necrosis, and in its chronic phase, due to immune reaction, fibrosis, and resulting electrical remodeling. Therapy is essentially supportive for arrhythmias in the acute phase of disease, which can last several weeks but may regress spontaneously. Even in chronic myocarditis, therapy is largely confined to antiarrhythmic drugs, with limited efficacy, and to implantable cardioverter-defibrillator (ICD) for higher-risk cases, such as those with hemodynamically unstable ventricular tachycardia (VT) and aborted sudden cardiac death. 2, 3, 10 Radiofrequency catheter ablation (RFCA) has been demonstrated to be effective in reducing VT occurrence in patients with Chagas cardiomyopathy. 11 In non-Chagasic myocarditis, isolated reports suggest that RFCA of VT may be effective, [12] [13] [14] but its safety and long-term efficacy in this setting is unclear. This study evaluates safety and effectiveness of RFCA in a series of consecutive patients with persisting drug-refractory VTs following a biopsy diagnosis of myocarditis. stence and/or a a a a a a aut u u u u u u u n d
Methods

Patient population
We enrolled 20 consecutive patients (15 males) with biopsy-proven myocarditis and drugrefractory VTs who had been referred for RFCA between January 2008 and December 2010. In all patients the diagnosis of viral myocarditis was based on Dallas and immunohistochemical criteria. 15 The study was approved by the institutional review board, and all patients gave their written informed consent. Non-invasive investigations before RFCA included chest X-rays, 12-lead ECG and color-Doppler echocardiography. Invasive characterization of the myocardial substrate was also performed before VT ablation and included coronary, left ventricular (LV) and right ventricular (RV) angiography, three-dimensional electro-anatomic mapping (EAM) and endomyocardial biopsy guided by EAM whenever low-voltage zones where observed, or otherwise performed at the interventricular septum. [16] [17] [18] 
Mapping and endocardial ablation procedure
Via transfemoral puncture, a quadripolar catheter was placed at the RV apex and the RV outflow tract; a ventricular stimulation study was performed with up to three extra-stimuli to induce VT. previous studies, the reference value for normal endocardium bipolar signal amplitude was set at 1.5 mV. 18, 21 In patients with hemodynamically tolerated VT, activation mapping, entrainment mapping and pace-mapping maneuvers were performed. If VTs were not inducible or were hemodynamically unstable, pace mapping was performed and areas of scar were circumscribed with radiofrequency (RF) pulses, delivered with a maximum power of 40 W and at a maximum temperature of 43°C.
After ablation, all patients were monitored in the electrophysiology laboratory for up to an hour; also, VT reinduction was attempted with up to three ventricular extra-stimuli with and without isoprenaline infusion.
Epicardial ablation procedure
In patients in whom endocardial ablation failed (including three who had undergone previous ablation at another Institution), epicardial RFCA was performed, with the same instrumentation described above, with the addition of epicardial mapping via the sub-xiphoid approach. 22 Intracardiac echocardiography (ICE) was used to assess the presence of possible pericardial effusion and to locate critical structures, such as the coronary arteries. After completing EAM, the above-mentioned criteria were used to select sites for RF pulses, which were delivered with a maximum power of 45 W and at a maximum temperature of 41°C. Ablation was performed remote from the left coronary arteries based on selective coronary angiography. In regions close to the phrenic nerve, high-output pacing (20 mA) was performed via the ablation catheter, and these locations were marked on the EAM. Post-ablation monitoring and reinduction attempts were performed as described above. Table 1 shows the clinical characteristics of the 20 enrolled patients (median age 42 years, 15 males). Pre-ablation echocardiography showed a median LV ejection fraction (LVEF) of 55% (45%-60%). (Table 1) EAM-guided biopsy was performed a median of 5 (3-5) months before ablation and showed in The patients had been suffering from documented ventricular arrhythmias for a median of 8 (6-24) months (range: 1-36 months) and all had proven refractory to antiarrhythmic therapy with 2.1±1.4 drugs, including amiodarone in 9 patients (45%). Three patients (15%) had been previously implanted with an ICD. Five (25%) presented with electrical storm, including all three ICD carriers. Three patients (15%) came to our attention following an unsuccessful previous RFCA at another institution.
Results
Patient characteristics
After ablation, one patient (5%) was implanted with an ICD before discharge because, in addition to having LVEF 35%, she also showed alternating bundle branch block and symptomatic paroxysmal 2 nd -degree type II atrioventricular block. 
Electrophysiologic features and short-term success of RFCA
Long-term outcome
After a median follow-up of 28 (11-48) months, 3/20 patients (15%) remained on antiarrhythmic drugs: 1 patient (5%) because of frequent polymorphic premature ventricular beats and 2 (10%) because clinical sustained VT recurred. Figure 5 shows long-term freedom from recurrent VT by the Kaplan-Meier survival analysis. ( Figure 5 )
One year after RFCA, there was a statistically significant increase in median LVEF (56% [45%-60%] vs. 60% [57%-63%], p < 0.001). In one case, after two years without VT episodes, the ICD was removed at the patient's request. 
Discussion
Main findings
This case series of consecutive patients with biopsy-proven myocarditis is the first study to which is consistent with current epidemiological data on myocarditis. 1, 8, 9 
Ventricular arrhythmias in myocarditis
Patients with myocarditis frequently display a wide spectrum of conduction disturbances, atrial and ventricular tachyarrhythmias. 23 Moreover, it has been demonstrated that continuing myocardial damage can persist even in the absence of overt inflammation, for example through the release of viral proteases capable of cleaving cytoskeletal dystrophin. 27, 28 The 2006 ESC/ACC/AHA guidelines on ventricular arrhythmias and sudden cardiac death 10 recommend drug therapy for life-threatening ventricular arrhythmias in myocarditis. In the acute phase, treatment is usually largely supportive. This can then be associated with possible ICD implantation if arrhythmias persist after the acute phase despite pharmacotherapy. RFCA is not mentioned at all in this context and is not contemplated in more specific guidelines on myocarditis. 2, 3 This absence reflects the lack of specific evidence on RFCA of VT in myocarditis, as most of the published evidence consists of case reports. [12] [13] [14] 29 A significantly larger body of published evidence is available on RFCA of VTs in patients with Chagas disease, a dilated cardiomyopathy due to infestation by the protozoan Trypanosoma cruzi. 11 In these patients, RFCA (both endocardial and epicardial) has been demonstrated to reduce VT recurrences, [30] [31] [32] which might in turn help reduce shocks in ICD carriers.
Similarly, effective RFCA has been reported in patients with cardiac sarcoidosis, 33,34 whose inflammatory granulomatous lesions often produce structural and clinical features resembling ARVC, representing an important cause of ventricular arrhythmias and sudden cardiac death.
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pharm m m m m m mac ac ac ac ac ac acot ot ot ot ot ot othe he he he he he hera ra ra ra ra ra rapy p p p p h n absence reflects the lack of s cific evidence on RFCA of V t his context and is not contemplated in more specific guidelin absence reflects the lack of specific evidence on RFCA of V We feel the choice of resorting to an irrigated ablation catheter is justified by the need for deeper RF lesions, in consideration of the high likelihood of intramural and/or subepicardial disease involvement.
Of the utmost interest is the finding that an epicardial RFCA was needed to suppress VT in 6/20 patients (30%), in five because endocardial lesions were ineffective and in one because they were not attempted as VT could only be induced by LV epicardial stimulation. This supports the concept that VTs may involve intramural or epicardial reentry circuits, as in fact, pathology and MRI studies indicate that in myocarditis the inflammatory process frequently starts from the epicardium. Accordingly, De Cobelli and colleagues found that in patients with chronic myocarditis presenting with either heart failure or ventricular arrhythmias and with MRI evidence of late enhancement, the latter was intra-mural in 62.5% of cases and subepicardial in the remaining 37.5%. 35 In our study, epicardial RFCA too was shown to be feasible, safe and effective.
The use of intracardiac echocardiography is a standard approach in VT ablation for all operators involved in this study. It proved useful not just in its ability to monitor for pericardial effusion, but also to locate structures of critical importance (such as the coronary arteries) and to confirm the adherence of EAM to ventricular anatomy. We feel this could also help to better visualize subtle morphological anomalies, such as microaneurysms, which were indeed present in one of our patients, or motion anomalies which might suggest presence of scar.
Study limitations
We recognize that the natural history of VTs in myocarditis has not been adequately ancement, the latter was intra-mural in 62.5% of cases and su %. 35 In our study, epicardial RFCA too was shown to be feasi by guest on June 23, 2017 http://circep.ahajournals.org/ Downloaded from chronic inflammation, this may not necessarily be the pathological substrate sustaining VT persistence indefinitely, as inflammation may become quiescent and still arrhythmias may be caused by "spent" residual myocardial damage. A distinction between ongoing inflammation and residual injury cannot be made on clinical grounds alone, and no precise evidence basis is available on whether the two possibilities carry different prognostic implications that might justify repeat invasive and/or costly investigations. In addition, we recognize that in view of the high incidence of intramural and subepicardial disease, in selected cases an epicardial approach to RFCA may be reasonable from the start, rather than defaulting to a second-line option as we did, and that ECG and/or MRI findings 35 might help guide this choice.
Conclusions
Radiofrequency catheter ablation of VTs in patients with chronic active myocarditis is safe, feasible and effective in eliminating VTs. Epicardial ablation should be considered as an important option to increase the success rate in these patients.
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